May 30,2018

Propeller Health Lands $20M to Develop Digital Medicine Platform Across Therapeutic Areas

Propeller Health, a digital therapeutics company, toay announced a $20 million funding round led by Aptar Pharma, with participation from existing investors Safeguard Scientifics, Social Capital, Hikma, 3M Ventures and SR One. Propeller plans to use the proceeds from the funding to support Propeller's investment in its pipeline of digital therapeutics and additional connected devices for the treatment of chronic respiratory disease, an area of continued market growth for the company. PropellerRead More

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Jun 23,2018

Mensia Technologies Raises 1.3 Million Euro to Introduce Koala Neurofeedback in Europe

Mensia Technologies, French MedTech startup, leads the new booming category of Digital therapeutics with its revolutionary « at home « neurofeedback, to train the brain and cure neuropsy disorders without drugs. Co-founder INRIA-IT2, existing shareholders and now HARA, which are business angels experts in medical device category, joined this fundraising. BPI de Rennes is also part of this tour.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Jun 29,2018

Neurologic-focused digital therapeutics group MedRhythms raises $5m

Early stage medtech company MedRhythms said today it raised $5.3 million in a Series A round of financing to help support its platform intended to use neurologic interventions to measure and improve walking. The Portland, Maine-based company said it initially intended to raise $4 million, but found “substantial interest” and ended up netting extra funds. MedRhythms added that it has already closed $5 million from the round.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Sep 05,2018

Mount Sinai spinoff raises $1.8M, launches enterprise digital therapeutic prescription tool

Rx.Health — a Mount Sinai Health System spinoff that has built an app prescription platform for enterprises — has raised $1.8 million in seed funding. According to a statement, the investment will help the company pursue new clients and support the launch of its digital therapeutics and patient engagement tool, Bulk Prescription.

FUNDING SEED

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 14,2018

DarioHealth Closes on $10,345,000 Through Private Placement Offering

DarioHealth, a leading global digital health company with mobile health and big data solutions, announced today that it has closed on a private placement offering with institutional and private investors for the sale of shares of the Company's common stock and shares of the Company's newly designated Series D convertible preferred stock.

FUNDING POST-IPO EQUITY
View Analyst & Ambassador Comments
Go to original news
Apr 04,2018

Virta Health Raises $45 Million to Expand Treatment for Type 2 Diabetes Reversal

Virta Health, the first company with a clinically-proven treatment to safely and sustainably reverse type 2 diabetes (T2D) and other chronic metabolic diseases without the use of medications or surgery, announced it has raised a $45 million Series B funding round, bringing the total equity funding to $75 million to date. Key existing investors including Venrock, Obvious Ventures, Creandum, Caffeinated Capital, and Max Levchin’s SciFi VC participated in the round, along with new investors including Founders Fund and Playground Global.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Mar 28,2017

Tilak Healthcare gets $2.7M for therapeutic mobile games

French startup Tilak Healthcare, which is developing video games intended to diagnose and follow-up with chronic diseases, has raised $2.7 million (2.5 million euros) from the iBionext Growth Fund. The fund is part of the French management company iBionext network, which identifies, funds and helps expand healthcare startups.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Jun 14,2017

Led by Cigna, Omada Health Nabs $50M to Expand Digital Therapeutics for Chronic Disease

Omada Health, a digital health company that helps health plans and employers tackle type 2 diabetes and heart disease in the most engaging, effective, and scalable way possible has raised $50 million in funding led by Cigna. The round also included participation and U.S. Venture Partners, Andreessen Horowitz, Norwest Venture Partners, Humana, Kaiser Permanente Ventures, Providence Ventures, dRx Capital, GE Ventures, Civilization Ventures and Sanofi Genzyme BioVentures. Omada also announced that Cigna is expanding its non-exclusive commercial partnership with Omada, adding the recognized Omada Program to Cigna’s suite of health improvement services. This will enable eligible Cigna-administered health plan customers may have no-cost access to Omada’s digital intensive behavioral counseling platform as a fully covered preventive benefit in the carrier’s health improvement program portfolio.

FUNDING SERIES C
View Analyst & Ambassador Comments
Go to original news
Jul 03,2017

Theranica Raises $6M to Combat Migraine

Theranica Bio-Electronics, a bio-medical technology company developing advanced electroceuticals for migraine and other prevalent diseases, announced the closing of its round A of financing, led by Lightspeed Venture Partners. Other investors participating in the round are LionBird venture capital firm and Corundum Open Innovation. The funds, totaling about $6M will be used mainly to complete the regulatory process of the company's first product, for acute treatment of migraine, and to bring the product to mass production.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Feb 03,2016

Pear Therapeutics raises $20M for digital combination interventions, starting with substance use disorders

Pear Therapeutics, which is developing interventions that combine digital tools and medications, has raised $20 million in a round led by 5AM Ventures, Arboretum Ventures, and Jazz Venture Partners, with participation from Bridge Builders Collaborative. The company raised its last round, which was undisclosed, in March 2015. Pear Therapeutics’s product, called eFormulations, combines medication for a specific condition with a digital therapy program. he eFormulations product will be prescribed by physicians to their patients. Depending on the patient's condition, the software component of the offering could include games, tracking tools, and other engagement features. Pear Therapeutics will use the funds to launch its first eFormulations, called reSET and reSET-O, which are designed to treat substance use disorder (SUD).

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Subscribe to FUNDING